Impact of a Perioperative Protocol on Length of ICU and Hospital Stay in Complex Spine Surgery.

BACKGROUND: In an attempt to improve patient care, a perioperative complex spine surgery management protocol was developed through collaboration between spine surgeons and neuroanesthesiologists. The aim of this study was to investigate whether implementation of the protocol in 2015 decreased total hospital and intensive care unit (ICU) length of stay (LOS) and complication rates after elective complex spine surgery. MATERIALS AND METHODS: A retrospective cohort study was conducted by review of the medical charts of patients who underwent elective complex spine surgery at an academic medical center between 2012 and 2017. Patients were divided into 2 groups based on the date of their spine surgery in relation to implementation of the spine surgery protocol; before-protocol (January 2012 to March 2015) and protocol (April 2015 to March 2017) groups. Outcomes in the 2 groups were compared, focusing on hospital and ICU LOS, and complication rates. RESULTS: A total of 201 patients were included in the study; 107 and 94 in the before-protocol and protocol groups, respectively. Mean (SD) hospital LOS was 14.8±10.8 days in the before-protocol group compared with 10±10.7 days in the protocol group (P<0.001). The spine surgery protocol was the primary factor decreasing hospital LOS; incidence rate ratio 0.78 (P<0.001). Similarly, mean ICU LOS was lower in the protocol compared with before-protocol group (4.2±6.3 vs. 6.3±7.3 d, respectively; P=0.011). There were no significant differences in the rate of postoperative complications between the 2 groups (P=0.231). CONCLUSION: Implementation of a spine protocol reduced ICU and total hospital LOS stay in high-risk spine surgery patients.

The role of the American Society of anesthesiologists physical status classification in predicting trauma mortality and outcomes.

BACKGROUND: Trauma prediction scores such as Revised Trauma Score (RTS) and Trauma and Injury Severity Score (TRISS)) are used to predict mortality, but do not include comorbidities. We analyzed the American Society of Anesthesiologists physical status (ASA PS) for predicting mortality in trauma patients undergoing surgery. METHODS: This multicenter, retrospective study compared the mortality predictive ability of ASA PS, RTS, Injury Severity Score (ISS), and TRISS using a complete case analysis with mixed effects logistic regression. Associations with mortality and AROC were calculated for each measure alone and tested for differences using chi-square. RESULTS: Of 3,042 patients, 230 (8%) died. The AROC for mortality for TRISS was 0.938 (95%CI 0.921, 0.954), RTS 0.845 (95%CI 0.815, 0.875), and ASA PS 0.886 (95%CI 0.864, 0.908). ASA PS + TRISS did not improve mortality predictive ability (p = 0.18). CONCLUSIONS: ASA PS was a good predictor of mortality in trauma patients, although combined with TRISS it did not improve predictive ability.

Ivermectin causes Cimex lectularius (bedbug) morbidity and mortality.

BACKGROUND: Bedbug infestations are increasing across North America and Europe, with more people presenting to Emergency Departments for treatment. Physicians cannot provide substantive treatment for people affected by bedbugs. STUDY OBJECTIVE: To determine if ivermectin, a relatively inexpensive and safe, long-acting oral anti-parasitic drug is able to cause bedbug morbidity and mortality. METHODS: We evaluated the effects of ivermectin on bedbugs using an artificial feeding membrane and mice and humans. Bedbug morbidity, mortality, and nymph molting was recorded. RESULTS: Using an artificial feeding membrane, bedbug mortality was 98% (n = 81) for 260 ng/mL ivermectin and 0% for 0 ng/mL ivermectin (control; n = 90) after 13 days. Mortality for bedbugs fed on mice injected with the human equivalent of 200 µg/kg ivermectin was 86% (n = 22), vs. 0% in the 0 µg/kg ivermectin (control; n = 21). Of the surviving nymphs, 0% exposed to ivermectin molted by day 75, vs. 80% in the control group by day 8. Bedbugs that fed once on human study subjects 3 h after consuming 200 µg/kg of oral ivermectin had a 63% (n = 24) 20-day mortality rate, vs. 8% (n = 24) in the control group. Of the surviving nymphs, 0% (n = 5) in the 3-h ivermectin group molted, vs. 80% (n = 10) of the control group. CONCLUSIONS: It may be possible that ivermectin could help eradicate, suppress, or prevent a bedbug infestation.